(Adnkronos) - "Il campo dei linfomi diffusi a grandi cellule si sta evolvendo molto rapidamente, grazie ad una serie di farmaci innovativi, che si stanno affiancando o, addirittura, in alcuni casi, sostituiscono la chemioterapia. Tra questi ricordiamo le terapie Car T e gli anticorpi monoclonali”. Così Marco Ladetto, presidente Fondazione italiana linfomi, a margine del 51° congresso nazionale Sie - Società italiana di ematologia, in svolgimento al MiCo di Milano dal 23 al 25 settembre e al quale è presente anche Sobi, azienda biofarmaceutica con focus su malattie ematologiche rare o poco conosciute, e oncoematologia.
Category
🗞
NewsTranscript
00:00The field of lymphoma diffuse cell is evolving very, very quickly with a whole series of
00:09innovative drugs that are being supported, even in some cases replacing chemotherapy.
00:15Among these, we remember the CAR-T cells, cells armed against lymphoma tumor cells,
00:21extremely powerful, but also all the new monoclonal antibodies, some of which act
00:26by stimulating the immune system to hit the lymphoma, like the more specific antibodies,
00:32others that carry out their effectiveness by bringing toxins, therefore poisonous and toxic substances,
00:39directly against the tumor cell, such as, for example, ipoilatuzumab and oncastuzumab.
00:44These are all extremely important and effective approaches that we must learn to know, develop, combine.
00:52Therefore, a vast field of research is opening up, which is certainly bringing, and will continue to bring,
00:58more and more important benefits for patients.
01:00The unmet needs are linked to the fact that these therapeutic devices must be integrated,
01:06combined and used better.
01:08So we have to learn to use what we already have best and, of course, we also have to develop
01:13some new treatments, new potentials, because there are certainly some particularly difficult patients,
01:20those who have the IP53 mutation or those who have certain genetic alterations that make them
01:25particularly resistant to the death induced by the treatments.
01:30We still need to work on this.
01:32In this, a combination of biological studies is very important, which allows us to better know
01:39the differences between various lymphomas and the use of new molecules in the context of well-conducted clinical experiments.